Bispecific T cell activating antigen binding molecules
AssigneeHoffmann-La Roche Inc.
InventorsChristian Klein, Marina Bacac, Anne Freimoser-Grundschober, Sylvia Herter, Joaquin Arribas, Rocio Vicario
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
Claims33
A T cell activating bispecific antigen-binding molecule comprising:
- (a) a first antigen-binding moiety which specifically binds to a first antigen;
- (b) a second antigen-binding moiety which specifically binds to a second antigen;
- wherein the first antigen is an activating T cell antigen and the second antigen is p95HER2, or the first antigen is p95HER2 and the second antigen is an activating T cell antigen;
- and
- wherein the antigen-binding moiety which specifically binds to p95HER2 comprises:
- (a) a heavy chain variable region comprising a heavy chain complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:
- 14, a heavy chain CDR 2 comprising the amino acid sequence of SEQ ID NO:
- 15, and a heavy chain CDR 3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- and
- (b) a light chain variable region comprising a light chain CDR 1 comprising the amino acid sequence of SEQ ID NO:
- 17, a light chain CDR 2 comprising the amino acid sequence of SEQ ID NO:
- 18, and a light chain CDR 3 comprising the amino acid sequence of SEQ ID NO:
- 19.
Dependencies are inferred from the claim text.